BofA analyst Kevin Fischbeck downgraded Centene to Underperform from Neutral with a price target of $85, down from $100, on what he sees as a worse risk/reward heading into redeterminations. The trajectory Centene has outlined implies a 13% EPS compound annual growth rate through 2025, but consensus "already assumes near-perfect execution" and he sees "more to lose than to gain in upcoming RFPs" given mounting headwinds, Fischbeck tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNC:
- Centene completes divestiture of Magellan Rx to Prime Therapeutics
- CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX
- Managed care company returns will be tough to keep replicating, WSJ says
- CENTENE SIGNS DEFINITIVE AGREEMENT TO DIVEST MAGELLAN SPECIALTY HEALTH
- EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE
